Resultats de la cerca - Kenneth W. Mahaffey

Refinar resultats
  1. 1
    Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment

    Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment per Byron Cryer, Kenneth W. Mahaffey

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Management of Patients With NSTE-ACS

    Management of Patients With NSTE-ACS per Fátima Rodríguez, Kenneth W. Mahaffey

    Publicat 2016
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    <p>Canagliflozin review – safety and efficacy profile in patients with T2DM</p>

    <p>Canagliflozin review – safety and efficacy profile in patients with T2DM</p> per Haroon Jakher, Tara I. Chang, Marilyn Tan, Kenneth W. Mahaffey

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    Dedicated kidney disease‐focused outcome trials with sodium‐glucose cotransporter‐2 inhibitors: Lessons from CREDENCE and expectations from DAPA‐HF, DAPA‐CKD, and EMPA‐KIDNEY

    Dedicated kidney disease‐focused outcome trials with sodium‐glucose cotransporter‐2 inhibitors: Lessons from CREDENCE and expectations from DAPA‐HF, DAPA‐CKD, and EMPA‐KIDNEY... per Jinnie J. Rhee, Meg Jardine, Glenn M. Chertow, Kenneth W. Mahaffey

    Publicat 2020
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  5. 5
    Characteristics of Digital Health Studies Registered in ClinicalTrials.gov

    Characteristics of Digital Health Studies Registered in ClinicalTrials.gov per Connie Chen, Robert A. Harrington, Sumbul Desai, Kenneth W. Mahaffey, Mintu P. Turakhia

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review

    Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review per Karin Rådholm, Jason Wu, Muh Geot Wong, Celine Foote, Gregory Fulcher, Kenneth W. Mahaffey, Vlado Perkovic, Bruce Neal

    Publicat 2018
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Reviewing the role of healthy volunteer studies in drug development

    Reviewing the role of healthy volunteer studies in drug development per Joyson Karakunnel, Nam Q. Bui, Latha Palaniappan, Keith T. Schmidt, Kenneth W. Mahaffey, Briggs Morrison, William D. Figg, Shivaani Kummar

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  8. 8
    Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection

    Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection per Roham T. Zamanian, Charles V. Pollack, Michael A. Gentile, Moira Rashid, J. Christian Fox, Kenneth W. Mahaffey, Vinicio de Jesús Pérez

    Publicat 2020
    Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  9. 9
    The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the <scp>CANVAS</scp> and <scp>CREDENCE</scp> Trials

    The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the <scp>CANVAS</scp> and <scp>CREDENCE</scp> Trials per Tu Ngoc Nguyen, Jie Yu, Vlado Perkovic, Meg Jardine, Kenneth W. Mahaffey, Clara K Chow, Clare Arnott, Richard I. Lindley

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials

    Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials per Zubin J. Eapen, W.H. Wilson Tang, G. Michael Felker, Adrian F. Hernandez, Kenneth W. Mahaffey, A. Michael Lincoff, Matthew T. Roe

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes per Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R. Matthews

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Glucose, insulin, and acute myocardial infarction: reply

    Glucose, insulin, and acute myocardial infarction: reply per Abhinav Goyal, Kenneth W. Mahaffey, Jyotsna Garg, José Carlos Nicolau, Judith S. Hochman, W. Douglas Weaver, Gustavo B.F. Oliveira, Thomas T. Todaro, Christopher B. Granger

    Publicat 2006
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion

    Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion per Matthew T. Roe, E. Magnus Ohman, Arthur Maas, Robert H. Christenson, Kenneth W. Mahaffey, Christopher B. Granger, Robert A. Harrington, Robert M. Califf, Mitchell W. Krucoff

    Publicat 2001
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  14. 14
    Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus

    Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus per Gemma A. Figtree, Karin Rådholm, Terrance D. Barrett, Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, David R. Matthews, Wayne Shaw, Bruce Neal

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  15. 15
    Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes

    Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes per Jingwei Li, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Brendon L. Neuen, Clare Arnott, Robin Simpson, Richard Oh, Kenneth W. Mahaffey, Hiddo J.L. Heerspink

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide

    Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide per James L. Januzzi, Jialin Xu, Jingwei Li, Wayne Shaw, Richard Oh, Roman Pfeifer, Javed Butler, Naveed Sattar, Kenneth W. Mahaffey, Bruce Neal, Michael K. Hansen

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin

    Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin per Muthiah Vaduganathan, Naveed Sattar, Jialin Xu, Javed Butler, Kenneth W. Mahaffey, Bruce Neal, Wayne Shaw, Norman Rosenthal, Roman Pfeifer, Michael K. Hansen, James L. Januzzi

    Publicat 2022
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

    Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure per Sok Cin Tye, Niels Jongs, Steven G. Coca, Johan Sundström, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Priya Vart, Hiddo J.L. Heerspink

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes

    Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes per Daniel Lindholm, Stefan James, Katja Gabrysch, Robert F. Storey, Anders Himmelmänn, Christopher P. Cannon, Kenneth W. Mahaffey, Philippe Gabríel Steg, Claes Held, Agneta Siegbahn, Lars Wallentin

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

    Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial per Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Peter Stein, Mehul Desai, Wayne Shaw, Joel Jiang, Frank Vercruysse, Gary Meininger, David R. Matthews

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: